(Q47970245)

7 February 2018

title

Clinical presentation and prognosis in MOG-antibody disease: a UK study (English)

1 reference

7 February 2018

1 reference

14

Angela Vincent

1 reference

7 February 2018

17

Jacqueline Palace

1 reference

7 February 2018

1

Maciej Jurynczyk

1 reference

7 February 2018

author name string

Silvia Messina

2

1 reference

7 February 2018

Mark R Woodhall

3

1 reference

7 February 2018

Naheed Raza

4

1 reference

7 February 2018

Rosie Everett

5

1 reference

7 February 2018

Adriana Roca-Fernandez

6

1 reference

7 February 2018

George Tackley

7

1 reference

7 February 2018

Shahd Hamid

8

1 reference

7 February 2018

Angela Sheard

9

1 reference

7 February 2018

Gavin Reynolds

10

1 reference

7 February 2018

Saleel Chandratre

11

1 reference

7 February 2018

Cheryl Hemingway

12

1 reference

7 February 2018

Anu Jacob

13

1 reference

7 February 2018

M Isabel Leite

15

1 reference

7 February 2018

Patrick Waters

16

1 reference

7 February 2018

language of work or name

English

0 references

publication date

9 November 2017

1 reference

7 February 2018

published in

Brain

1 reference

7 February 2018

volume

140

1 reference

7 February 2018

issue

12

1 reference

7 February 2018

page(s)

3128-3138

1 reference

7 February 2018

Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children

cites work

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

BLADDER DYSFUNCTION IN MULTIPLE SCLEROSIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

The spectrum of MOG autoantibody-associated demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

The spectrum of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWX276

21 January 2018

Identifiers

DOI

10.1093/BRAIN/AWX276

1 reference

7 February 2018

1 reference

7 February 2018